Impact of the COVID-19 pandemic: Community and hospital shared pharmaceutical care model. Satisfaction and acceptability of patients with HIV infection on antiretroviral treatment

• Published in: Revista española de quimioterapia Vol. 35; no. 1; pp. 71 - 75
• Main Authors: Molas, M E, Knobel, H, Ferrández, O, de Antonio Cuscó, M, Carballo Martínez, N, Rodríguez Caba, C, Luque, S, Guelar, A, Castañeda Espinosa, S, Grau, S
• Format: Journal Article
• Language: English
• Published: Spain Sociedad Española de Quimioterapia 01.02.2022
• Subjects: Brief Report; COVID-19; Cross-Sectional Studies; HIV Infections - drug therapy; HIV Infections - epidemiology; Hospitals; Humans; Pandemics; Patient Satisfaction; Personal Satisfaction; Pharmaceutical Services; SARS-CoV-2; COVID-19; pharmaceutical care; Antiretroviral therapy
• ISSN: 0214-3429; 1988-9518
• DOI: 10.37201/req/055.2021

The health crisis due to the COVID-19 pandemic is a challenge in the dispensing of outpatient hospital medication (OHM). Models of Antiretroviral Therapy (ART) based on community pharmacy support (ARTCP) have proven to be successful. The aim was to evaluate the degree of satisfaction, acceptability and limitations of the implementation of ARTCP, in the context of a pandemic, in our environment. Descriptive cross-sectional study carried out in a Barcelona hospital, during the months of July-November 2020. A telephone survey was carried out via a questionnaire on the quality dimensions of the model (degree of satisfaction, acceptability) and associated inconveniences. Data collected: demographics, antiretroviral treatment (ART), concomitant medication, drug interactions (DDIs), CD4 lymphocyte count and plasma viraemia. Data analysis included descriptive statistics. A total of 533 (78.0%) HIV patients receiving ART were included. 71.9% (383/533) of these patients were very satisfied and 76.2% preferred attending the community pharmacy rather than the hospital. The mean satisfaction rating was 9.3 (DS: 1.4). The benefits reported were: 1) proximity to home (406: 76.1%); 2) lower risk of contagion of COVID-19 (318: 59.7%); 3) shorter waiting time (201: 37.1%); 4) time flexibility (104: 19.5%); 5) reduction of financial expenses (35: 6.57%). A total of 11 (2%) patients reported no benefit. Only 22.9% reported disadvantages associated with ARTCP: 1) lack of privacy (65: 12.2%); 2) lack of coordinationorganization (57: 10.7%). The COVID-19 pandemic has had an impact on the provision of pharmaceutical care for HIV patients. The ARTPC model has proved efficient, with patients reporting a high degree of satisfaction.